Global Topical Androgen Receptor Inhibitors Market Based on Indication: (Acne, Alopecia Based on Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Topical Androgen Receptor Inhibitors Market:

The global Topical Androgen Receptor Inhibitors Market is projected to reach a valuation of USD 1,65,085.36 Mn by 2032 at a CAGR of 15.50%, from USD 39,074.08 Mn in 2022.

Topical Androgen Receptor Inhibitors (TARIs) are usually used for mild to moderate acne where stronger treatments can cause significant dryness or peeling of the skin. Topical androgen receptor inhibitors are also typically considered less irritating or limiting to daily activities than benzoyl peroxide since they are applied once a day rather than twice.

Recent research has shown that the use of topical androgen receptor inhibitors to treat acne is better than topical 5-alpha reductase inhibitors. Topical androgen receptor inhibitors reduce the effects of testosterone on the skin, which decreases sebum production. They also have anti-inflammatory properties that can reduce the redness associated with acne outbreaks.

Topical Androgen Receptor Inhibitors are drugs that are used to treat acne, dermatitis, psoriasis, or certain other skin conditions. They may be prescribed as one topical medication or in combination with other medications depending on the individual’s needs. Topical androgen receptor inhibitors work by reducing the ability of Dihydrotestosterone (DHT) to bind to receptors in cells which decreases oil production and inflammation triggering factors.

In recent years, the medical community has sought a way to limit the negative side effects of androgen receptor inhibitors. For this reason, they have sought a new drug that would increase effectiveness and not carry any of these negative side effects. The latest advancement in this field is topical androgen receptor inhibitors. This new type of drug is applied directly to the skin where it interacts with the cells in that area, limiting the production of DHT.

Global Topical Androgen Receptor Inhibitors Market Revenue (USD Mn), 2021–2031:

For the last 50 years, chemotherapy has been used to treat cancer patients. Chemotherapy works by poisoning cancer cells and some good cells in the body, but new drugs are being developed that target specific parts of cancer cells with lesser side effects than traditional chemo. Topical Androgen Receptor Inhibitors (TARIs) is one such drug that works on prostate cancer cells within the prostate gland without affecting other tissue in the body.

Topical androgen receptor inhibitors, or TARIs, are a new form of treatment for patients with abnormal prostate size. These drugs work by inhibiting the binding of testosterone to cell receptors in the prostate that can cause enlargement. In recent studies, this new drug has been shown to be more effective in slowing down the progression of Benign Prostatic Hyperplasia (BPH) symptoms in comparison to current treatments such as finasteride and dutasteride.

The global topical androgen receptor inhibitors’ market growth trajectory is expected to be hampered by imposed stringent regulatory restrictions. Side effects such as skin irritation or redness are also expected to potentially limit the global market for topical androgen receptor inhibitors over the forecast period.
In recent years, the FDA has approved a number of topical agents that selectively inhibit androgen activity in skin cells. These include 2 topical agents called eflornithine cream and 17-beta-estradiol cream. Other topical agents include low-dose 5α-reductase inhibitors, which are capable of preventing the conversion of testosterone to Dihydrotestosterone (DHT).

A new class of drugs may be a promising option for the treatment of prostate cancer. Topical androgen receptor inhibitors work by blocking the production of testosterone in tumor cells, which drastically reduces the number of cells that can grow. Early trials have been successful, with some patients being free of disease progression for more than a year after treatment.

With the trend of men becoming more conscious about their appearance, there has been an increase in demand for treatments for male pattern baldness. One of the most popular treatments for this disorder is the use of Topical Androgen Receptor Inhibitors (TARIs).

The use of topical androgen receptor inhibitors has become a popular treatment option for men who have enlarged prostate glands, or BPH. It is believed that testosterone plays a role in the occurrence of BPH, and when it is applied to the scalp in small doses, it blocks the effects of testosterone on prostate tissue.
Recent developments in hormone therapy have yielded new treatments with fewer side effects rather than testosterone replacement treatments.

Recently, a study was conducted, in which it was found that a topical formulation containing an androgen receptor inhibitor, bazedoxifene, showed a reduction in the number of erythema lesions of rosacea patients.

In August 2020, the United States Food and Drug Administration (USFDA) approved Winlevi® (clascoterone cream 1%), a topical androgen receptor inhibitor developed by Cosmo Pharmaceuticals, for the treatment of acne in patients aged 12 and above.

This research report on the global Topical Androgen Receptor Inhibitors Market includes major company profiles such as:

• Cosmo Pharmaceuticals
• Kintor Pharmaceutical Limited
• Sun Pharmaceutical Industries Limited
• Aranda Pharma Ltd.
• Selleck Chemicals
• Others.

The Global Topical Androgen Receptor Inhibitors Market Segmentation is Based on Indication, Distribution Channel, and Region:

Based on Indication:

• Acne
• Alopecia

Based on Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Based on Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

For the Topical Androgen Receptor Inhibitors Market research study, the following years have been considered to estimate the market size: